Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

ADHD

This page shows the latest ADHD news and features for those working in and with pharma, biotech and healthcare.

Neurodiversity and healthcare communications – do we know enough and do we do enough?

Neurodiversity and healthcare communications – do we know enough and do we do enough?

This means they behave, think, process or interpret information in ways that differ to most other people and includes conditions such as: autism, ADHD, dyslexia, dyspraxia, dyscalculia, dysgraphia and tic disorders

Latest news

More from news
Approximately 15 fully matching, plus 127 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    With recent FDA approval of EndeavorRx by Akili, a ‘first of its kind attention treatment for children with ADHD delivered through a captivating video game experience’, and multiple innovative technologies in

  • Deal Watch March 2017 Deal Watch March 2017

    contingent payments for the ADHD company Neurovance; Shanghai Fosun paid $90m for a majority interest in Breas (see above); Ascendis Health paid R375m ($29m) for the Southern Africa operations of Cipla ... 320. Neurovance. Otsuka. Acquisition. Portfolio,

  • A rare talent A rare talent

    It allowed us to solidify our position as the world's largest rare disease company and we now are the leaders in haematology, lysosomal storage disorders with strong capabilities in ADHD

  • Challenging perceptions Challenging perceptions

    We try to be recognised as patient-centric by supporting and helping the overall ADHD community. ... Harnessing technology. Shire's communications efforts in ADHD have for some time included digital technology.

  • Pharma deals in February 2015 Pharma deals in February 2015

    in-house clinical and preclinical pipeline targeting serious diseases with blockbuster potential eg Alzheimer's disease, ADHD, metabolic disease, schizophrenia, migraine. ... Its initial development was focused on ADHD and other neurological diseases.

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Shire elects new chair Shire elects new chair

    During that time Shire has grown substantially, although has struggled in recent years with generic competition for big-selling attention deficit-hyperactivity disorder (ADHD) drug Adderall XR and plans to downsize

  • Bray Leino opens health and wellbeing PR practice Bray Leino opens health and wellbeing PR practice

    She has worked on campaigns for ADHD brands and public affairs for Shire Pharmaceuticals: cardiology products for AstraZeneca, Sanofi and Eli Lilly; mental health for Wyeth; diagnostics and devices for Roche

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...

Quick links